Apotex Corp. launched imatinib mesylate tablets

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

APOTEX Corp. has launched imatinib mesylate tablets, the generic equivalent of Gleevec by Novartis. Apotex’s Imatinib Mesylate Tablets are now available in 100mg and 400mg strengths. According to IMS Health, Gleevec had approximately $2.4 billion in sales in the 12 months ending in May 2016. jQuery(document).ready(function(){ jQuery('.people-thumb + p > span.has-red-100-color, .people-thumb + p >...

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

The field of surgical oncology has undergone transformative advancements over the last decade. From refining minimally invasive techniques to leveraging immunotherapy and viral oncolytics, our collective goal remains the same: improving patient outcomes while reducing treatment burden. At City of Hope, we have prioritized accelerating the translation of laboratory discoveries into clinical applications, and nowhere is this more evident than in our work with oncolytic viruses, remote surgery, and the integration of AI in surgical decision-making.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login